Prediman Shah, MD
Cardiovascular Disease · Los Angeles, CANPI 1447394036
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,080 of the $19,500 with a category attached, or 67.1%. 4 manufacturers reported payments, led by Amgen at 36.6% of the total. Reporting peaked in 2021 at $9,125 and has fallen 77.0% since, to $2,100 in 2022.
Across 8 payments — averaging $2437.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Kaneka Medical America LLC$6K
- Novartis$6K
- Novo Nordisk$65
Across 59 payments — averaging $3351.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$191K
- Amgen$5K
- Aegerion Pharmaceuticals, Inc.$1K
- Amryt Pharma Holdings Ltd$349
- Chiesi USA, Inc.$175
What the payments were for
- Consulting fees$13,08067%
- Speaking & faculty fees$6,35633%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $7,140 |
| Kaneka Medical America LLC | 1 | $6,356 |
| Novartis | 4 | $5,940 |
| Novo Nordisk | 2 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIPOSORBER$6,356
- LEQVIO$4,020
How this compares
$19,500 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $111,159 |
| Repatha SureclickEvolocumab | 103 | $82,020 |
| Praluent PenAlirocumab | 32 | $26,741 |
| BrilintaTicagrelor | 20 | $14,706 |
| XareltoRivaroxaban | 13 | $13,754 |
| VascepaIcosapent Ethyl | 15 | $9,299 |
| LivaloPitavastatin Calcium | 13 | $8,275 |
| Ambien CrZolpidem Tartrate | 13 | $8,150 |
| Rosuvastatin Calcium | 297 | $4,924 |
| Ezetimibe | 156 | $4,755 |
| Carvedilol ErCarvedilol Phosphate | 12 | $2,836 |
| CozaarLosartan Potassium | 11 | $1,971 |
| Atorvastatin Calcium | 161 | $1,516 |
| Telmisartan | 35 | $1,280 |
| Eplerenone | 17 | $1,026 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.